Tag Archives: Strategy

Recasting Big Pharmas R&D Role: Wellcome Trust or Wal-Mart?

By William Looney | Published: September 15, 2010
New research suggests it’s time industry took a radically different approach to drug development, leaving compound innovation to others while mobilizing its global scale and promotional muscle to drive timely acceptance in the marketplace. The biggest strategic issue confronting Big Pharma today is balancing that legacy of ”big” — maintaining the capacity to invest in the [...]
Posted in R&D, Strategy | Also tagged , | Leave a comment

MedImmune Bets Its Fate on “Biobetters”

By Walter Armstrong | Published: September 9, 2010
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Posted in Biotech, Deals, Global, R&D, Strategy | Also tagged , , , , , | 1 Comment

How Do We Raise R&D Productivity?

By Julian Upton | Published: September 7, 2010
That’s the big question that no one has answered yet. So perhaps its worth breaking it down into smaller parts, suggests Dr Brian D Smith. An ill-posed question is a mathematician’s term that well describes what many Big Pharma companies are asking themselves, namely, how can we raise R&D productivity? It’s ill-posed because it has not [...]
Posted in Europe, Global, Guest Blog, Marketing, Strategy | Also tagged , , | Leave a comment

Updated IMS Forecast Predicts Market Growth

By Oriana Schwindt | Published: April 20, 2010
If you look closely at the thunderclouds hovering over pharma, there is a ray of light peeking through the gloom—IMS’ updated 2009-2014 forecast has come in, and it’s a far cry from the unmitigated doom of recent years. Market growth in 2009 was 7 percent, a vast improvement over 2008’s 4.8 percent, and IMS expects [...]
Posted in Strategy | Also tagged , , | Leave a comment

AstraZeneca, BMS Announce Layoffs and Buyouts

By George Koroneos | Published: October 21, 2009
AstraZeneca was the topic of conversation this week as word broke that the company is offering buyout deals to every member of its 5,500 US sales force. “AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they are [...]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment